Tenofovir Disoproxil

Tenofovir Disoproxil (CAS No.: 201341-05-1) is a synthetic small molecule nucleotide analog prodrug and a core research reagent in antiviral drug discovery, particularly for mechanistic studies of reverse transcription biology, where intracellular esterase mediated conversion yields tenofovir and subsequent phosphorylation generates tenofovir diphosphate, an active metabolite that competitively engages viral reverse transcriptase at the nucleotide binding level and functions as a DNA chain terminating substrate analog during nascent viral DNA synthesis; within this framework it is categorized as a nucleotide reverse transcriptase inhibitor and is widely used to investigate HIV 1 and hepadnavirus replication pathways, resistance associated polymerase variation, and structure function relationships in viral polymerase inhibition, with reported in vitro antiviral effects for this class generally observed from nanomolar to micromolar range depending on cell type, viral strain, metabolic activation capacity, and assay format, while experimental deployment commonly includes immortalized cell based infection systems, primary cell comparative assays, and animal model pharmacology and exposure response studies to support lead profiling and benchmark comparisons against related nucleotide analogs, and the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.